

4133
TW

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Guo Q. Shi, et al

Serial No. : 10/522,259 Case No.: 21096P Art Unit:
4133

Filed : January 25, 2005

For : PPAR ALPHA SELECTIVE COMPOUNDS FOR THE
TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID
DISORDERS

Examiner:
Joseph S. Kudla

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO COMMUNICATION CONCERNING THE RESPONSE TO
RESTRICTION REQUIREMENT

Sir:

In response to the Communication concerning the Response to the Restriction Requirement dated January 17, 2008, the applicants make the following change in the election of species:

- The therapeutic class of compounds HMG-CoA Reductase inhibitors, and the specific compound atorvastatin, are elected as a species for Claim 30, which is directed to compositions comprising a compound of Claim 1 and one or more other active ingredients. The previous election of dipeptidyl peptidase-4 inhibitors is withdrawn. Claim 30 reads on the newly elected species. The election made above is supported in the application at page 22, lines 8-9.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.


MERCK & CO., INC.

By Patricia R. Ryan Date 1-28-2008

This is believed to be a full and complete response to the communication and the original Restriction Requirement. It is respectfully requested that the generic claims be rejoined once the species claims are determined to be allowable. If the examiner has any further questions regarding the Restriction Requirement, he is invited to telephone the undersigned attorney.

Respectfully submitted,

By


James L. McGinnis
Reg. No. 34,387
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0641

Date: January 28, 2008